Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ImmunoGen’s ovarian cancer drug misses Phase III primary endpoint

The study failed to meet its primary endpoint of progression-free survival (PFS) in ovarian cancer patients. Credit: skeeze on Pixabay.



  • ImmunoGen’s mirvetuximab soravtansine Phase III data

Go Top